Purchase Order 75N93024P00383

Award Date 2/27/24
Potential Completion Date 2/26/25
Potential Value $55K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Piscataway, NJ 08854, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, provides Genscript USA Inc. with $137,250.00 to deliver monoclonal antibodies and plasmid services. The firm-fixed price purchase order has an ultimate completion date of August 31, 2025. Genscript USA Inc. is a biotechnology company in Piscataway, New Jersey that specializes in molecular biology products and services for federal agencies....
This firm-fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, to Genscript USA Inc., a for-profit biotechnology company. The $118,272.00 contract is for the provision of customized antibody expressions and plasmid preparations to support biomedical research and public health initiatives. The award has a completion date of November 1, 2020 and does not include a set-aside designation. Genscript...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Genscript USA Inc., a for-profit biotechnology company based in Piscataway, New Jersey. The $164,700.00 firm fixed-price purchase order is for monoclonal antibodies and plasmids services, with a completion date of June 14, 2026. The contract does not have a set-aside designation. Genscript is a key supplier of...
Genscript USA Inc. has been awarded a $24,705 firm fixed price purchase order by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to provide services for creating customized monoclonal antibodies and plasmids in support of the agency's biomedical research efforts. As the prime contractor, Genscript will leverage its expertise in gene synthesis and monoclonal antibody development to deliver the requested biological products and services. This contract...
This is a $97,722.00 firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the provision of monoclonal antibodies and plasmids services to support NIAID's research initiatives, with a completion date of September 19, 2025. This contract is not designated as a set-aside....
The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) awarded a $78,507.00 firm-fixed-price contract to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey, for Genscript Monoclonal Antibodies and Plasmid Services. This sole-source contract supports NIAID's Laboratory of Immunogenetics (LIG), which is expanding its work on isolating human monoclonal antibodies against COVID-19, malaria, and tuberculosis. The contract...
This is a $164,700 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is for the provision of monoclonal antibodies and plasmids services to support critical research initiatives, with a period of performance through June 15, 2026. While the contract does not have a set-aside...
This federal contract award is for $17,568 to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS). The contract is for monoclonal antibodies and plasmids services to support biomedical research and public health initiatives. While the contract does not have a set-aside designation, Genscript has received other prime and...
This is a $1,147,346.00 firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Genscript USA Inc., a for-profit biotechnology company. The contract is for customized biological services to support the development and testing of therapeutic antibody and vaccine candidates by NIAID's Vaccine Research Center. This includes services such as plasmid preparation, protein production, and gene to...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $13,459 purchase order to Genscript USA Inc. to provide custom subcloning and antibody sequencing services in support of the agency's biomedical research efforts. Work will be performed by Genscript in Piscataway, New Jersey over a three-month period concluding in early October 2023. The firm fixed price contract was awarded under an unidentified agency-wide...

Genscript USA Inc. was awarded a $54,900 firm-fixed price purchase order by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases to provide customized antibody and plasmid preparation services. The award is associated with a pre-solicitation notice indicating the NIAID's intent to negotiate on a sole-source basis with Genscript for 100 customized antibodies and 200 plasmid preparations to support identification of potential vaccines for malaria, tuberculosis, and COVID-19. Delivery of the antibodies and plasmids must occur within 4-6 weeks at a unit price not exceeding $500 per antibody and $25 per 100 micrograms of plasmid. Performance is to be completed by February 26, 2025 at Genscript's location in Piscataway, New Jersey. No set-aside designation was applied to this award.

Generated 2/27/24, 4:26 PM